567 related articles for article (PubMed ID: 14577020)
21. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
[TBL] [Abstract][Full Text] [Related]
22. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Gralow J
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S54-62. PubMed ID: 15807925
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates in the prevention of bone metastases: current evidence.
Diel IJ
Semin Oncol; 2001 Aug; 28(4 Suppl 11):75-80. PubMed ID: 11544581
[TBL] [Abstract][Full Text] [Related]
24. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
Diel IJ; Solomayer EF; Bastert G
Cancer; 2000 Jun; 88(12 Suppl):3080-8. PubMed ID: 10898355
[TBL] [Abstract][Full Text] [Related]
26. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.
Romanus D; Iscoe N; Deangelis C; Shear N; Einarson TR
Support Care Cancer; 2004 Dec; 12(12):844-51. PubMed ID: 15235902
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates as treatment of bone metastases.
Holen I; Coleman RE
Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
[TBL] [Abstract][Full Text] [Related]
28. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
Fick EM; Katalinic A; Waldmann A
Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
30. Aredia: the once-monthly infusion for the treatment of bone metastases.
Lipton A
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
[TBL] [Abstract][Full Text] [Related]
31. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
32. [Bisphosphonates in oncology].
Kurth AA; Heidenreich A; Diel I
Orthopade; 2007 Feb; 36(2):131-5. PubMed ID: 17252255
[TBL] [Abstract][Full Text] [Related]
33. Use of intravenous bisphosphonates in older women with breast cancer.
Giordano SH; Fang S; Duan Z; Kuo YF; Hortobagyi GN; Goodwin JS
Oncologist; 2008 May; 13(5):494-502. PubMed ID: 18515734
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant bisphosphonate therapy: the future.
Paterson AH
Semin Oncol; 2001 Aug; 28(4 Suppl 11):81-5. PubMed ID: 11544582
[TBL] [Abstract][Full Text] [Related]
35. The role of bisphosphonates in breast cancer.
Coleman RE
Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
[TBL] [Abstract][Full Text] [Related]
36. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
[TBL] [Abstract][Full Text] [Related]
37. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates and radiation therapy for palliation of metastatic bone disease.
Hoskin PJ
Cancer Treat Rev; 2003 Aug; 29(4):321-7. PubMed ID: 12927572
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Diel IJ; Solomayer EF; Bastert G
Clin Breast Cancer; 2000 Apr; 1(1):43-51. PubMed ID: 11899389
[TBL] [Abstract][Full Text] [Related]
40. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
